Find Clinical Trial

Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes


← Back
Study Phase

Phase 4

Therapeutic Area

Metabolism

IndicationDiabetes - Type II
SponsorServier (Tianjin) Pharmaceutical Co. LTD.
Active substance/
Medical device

GLICLAZIDE,
S005702

Active Substance CodeS005702
Protocol CodeIC4-5702-205-CHN
NCT CodeNCT00736515


Documents and links

Scientific publication READ MORE



Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility